A5042723655- Prostate Cancer Diagnosis and Treatment
- Radiation Therapy and Dosimetry
- Hemophilia Treatment and Research
- Health Systems, Economic Evaluations, Quality of Life
- Glioma Diagnosis and Treatment
- Diabetes Management and Education
- Multiple Myeloma Research and Treatments
- Chronic Disease Management Strategies
- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Prostate Cancer Treatment and Research
- Meningioma and schwannoma management
- Diabetes Management and Research
- Renal Diseases and Glomerulopathies
- Pituitary Gland Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Lung Cancer Research Studies
- Global Cancer Incidence and Screening
- Cardiac pacing and defibrillation studies
- Complement system in diseases
- Renal Transplantation Outcomes and Treatments
- Healthcare Policy and Management
- Cardiovascular Function and Risk Factors
- Radiopharmaceutical Chemistry and Applications
- Hepatitis C virus research
Tris Pharma (United States)
2024
Novartis (United States)
2024
Kaiser Permanente San Francisco Medical Center
2024
University of Maryland, Baltimore
2015-2022
Roche (United States)
2021
University of Baltimore
2018-2020
Massachusetts General Hospital
2019
Johns Hopkins University
2019
West Pharmaceutical Services (United Kingdom)
2018
Duquesne University
2013-2015
Abstract Background Hypofractionated-SRS (HF-SRS) may allow for improved local control and a reduced risk of radiation necrosis compared to single-fraction-SRS (SF-SRS). However, data comparing these two treatment approaches are limited. The purpose this study was compare clinical outcomes between SF-SRS versus HF-SRS across our multi-center academic network. Methods Patients treated with or brain metastasis from 2013 2018 5 oncology centers were retrospectively reviewed. dosing...
Meningiomas express the somatostatin receptor (SSTR), which normal bone and brain lack. PET imaging with SSTR ligands such as 68 Ga-DOTATATE have been recently shown to aid in identification of menginiomas. We hypothesize that PET/CT conjunction MRI aids radiation (RT) target volume delineation evaluating treatment response.Nineteen patients meningiomas underwent for RT planning and/or post-treatment follow-up. were grade I (n = 9) or not biopsied 8) frequently involved base skull 10). Ten...
As a means of limiting normal tissue toxicity, proton-beam therapy (PBT) is an emerging radiation modality for glioblastoma (GBM) reirradiation. However, data recurrent GBM treated with PBT reirradiation limited. Therefore, we analyzed treatment patterns, toxicities, and clinical outcomes patients using the multi-institutional Proton Collaborative Group registry.Prospectively collected who underwent while enrolled in study 01-009 (NCT01255748) were analyzed. We evaluated overall survival...
Abstract Purpose Stereotactic radiation therapy (SRT) and immune checkpoint inhibitors (ICI) may act synergistically to improve treatment outcomes but also increase the risk of symptomatic necrosis (RN). The objective this study was compare for patients undergoing SRT with without concurrent ICI. Methods materials Patients treated BMs single or multi-fraction were retrospectively reviewed. Concurrent ICI (SRT-ICI) defined as administration within 3 months SRT. Local control (LC), (RN)...
Patient-level benefits of proton beam therapy (PBT) relative to photon for prostate cancer (PC) continue be the focus debate. Although trials comparing two modalities are underway, most being conducted using "conventional" PBT (passive scattering/uniform scanning [PS/US]) rather than pencil (PBS). The dosimetric PBS well-known, but comparative data limited. This analysis compares toxicity rates with those PS/US in a prospective multicenter registry.We evaluated acute/late gastrointestinal...
Abstract Objectives To assess physician perspectives on perceived barriers and facilitators to type 2 diabetes self-management (DSM) in a primary care setting. Methods The study utilized survey methodology measure of physicians DSM the challenges they face managing patients with poor glycaemic stability. Demographic practice site-related information were also collected. Key findings Of 21 who responded (53.8% response rate), 71.2% aged 50 years or older, 54.2% had ≥25 clinical experience,...
Background: Despite the increasing worldwide utilization of stereotactic body radiation therapy (SBRT) for prostate cancer, there are no known summative data regarding its safety and efficacy. To address this knowledge gap, we conducted a PRISMA-guided systematic review meta-analysis prospective SBRT trials. Results: Fourteen trials with total 2,038 patients were included. Median follow-up was 37 months (range 6-55 months). Most had cT1-T2a, Gleason ≤7 disease median pre-treatment PSAs 5-10;...
Although pencil beam scanning (PBS) is the most conformal method for proton therapy (PBT) delivery, it unknown if outcomes differ compared to treatment with passive scatter/uniform (PS/US). This analysis compares patient reported (PRO) changes following PBS and PS/US prostate cancer (PC) in a prospective multicenter registry study.We evaluated PROs Expanded Prostate Cancer Index Composite (EPIC) instrument men localized PC enrolled PCG 001-09 (NCT01255748). were assessed at baseline through...
The landscape of treatment for multiple myeloma (MM) has significantly changed over the last decade due to novel agents that have shown superiority in efficacy such as proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) traditional therapies. However, real-world utilization these new not been studied well. This study evaluated year-to-year changes choices a cohort patients aged 66 or older Surveillance, Epidemiology, End Results (SEER) registry linked with Medicare claims...
Previous studies assessing the impact of United States Preventive Services Task Force (USPSTF) recommendations on utilization prostate-specific antigen (PSA) screening have not investigated longer-term impacts 2008 nor they 2012 in Medicare population. This study aimed to evaluate change PSA screening, post-2008 and USPSTF recommendations, assessed trends determinants receipt population.This retrospective male beneficiaries utilized Current Beneficiary Survey data linked administrative...
Purpose The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with different states assessed this are unknown, limiting our ability to perform cost-utility analyses. This study aimed map EPIC EuroQoL-5D-3L (EQ5D) generate EQ5D utilities. Methods and materials a secondary analysis of prospective, randomized non-inferiority trial, conducted between 04/2006...
Objectives There has been a rapid increase in the number of one- and two-room proton beam therapy (PBT) centers, which may be limited patients they can treat. The objective this study was to analyze impact 'clinical benefit score' (CBS), utilized as method for treatment prioritization PBT operating 'cost-neutral' proton-photon payer environment. Materials & methods This includes considered at center that initially had only one or two rooms available clinical use. Patients were prospectively...